Insmed’s (INSM) Buy Rating Reiterated at Guggenheim
Guggenheim reiterated their buy rating on shares of Insmed (NASDAQ:INSM – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $101.00 target price on the biopharmaceutical company’s stock. INSM has been the subject of a number of other research reports. Wells Fargo & Company increased their price […]
Guggenheim reiterated their buy rating on shares of Insmed (NASDAQ:INSM – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $101.00 target price on the biopharmaceutical company’s stock. INSM has been the subject of a number of other research reports. Wells Fargo & Company increased their price […]
